Glioblastoma is among the most deadly forms of cancer. With treatment, the median survival time for people diagnosed with this type of brain cancer is 15 to 16 months.
But a new study shows that an immunotherapy drug could extend the life of glioblastoma patients if administered prior to surgery to remove tumors.
Researchers suspect that this is because the treatments awaken dormant T cells present in the tumor, which then can help fight the cancer wherever it appears in the brain. If the tumor is removed first, those cells are lost.
[…] “This is the first hint that immunotherapy can have a clinical benefit for patients with malignant brain tumors — and help prevent future recurrences,” added Robert Prins, who is also affiliated with the Parker Institute for Cancer Immunotherapy.